Drug Search Results
More Filters [+]

Serlopitant

Alternative Names: serlopitant, vpd-737, mk-0594, mk0594, mk 0594
Latest Update: 2022-12-23
Latest Update Note: Clinical Trial Update

Product Description

Serlopitant, an oral, once-daily neurokinin 1 receptor antagonist, for treatment of psoriatic pruritus in a phase 2, randomized clinical trial (NCT03343639).

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vyne Therapeutics
Company Location: BRIDGEWATER NJ 08807
Company CEO: David Domzalski
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Serlopitant

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Epidermolysis Bullosa|Pruritus

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT03836001

P2

Completed

Epidermolysis Bullosa|Pruritus

2021-12-06

Recent News Events